-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In patients with intracranial arterial stenosis, the dual antiplatelet therapy (DAPT) in the prevention of recurrent stroke with a single antiplatelet therapy (SAPT) long-term benefits in the prevention of recurrent stroke has not been clear
.
Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, the researchers aimed to compare the DAPT joint cilostazol and clopidogrel or aspirin efficacy in patients with intracranial arterial stenosis and SAPT clopidogrel or aspirin And safety
.
These patients were recruited into the antiplatelet combined with cilostazol stroke prevention study, a randomized controlled trial conducted in Japanese patients at high risk of ischemic stroke
.
Researchers compared DAPT and SAPT in at least 50% of patients with ischemic stroke and symptomatic or asymptomatic intracranial arterial stenosis and bleeding events
.
The patients were divided into two groups: 275 were assigned to receive DAPT, and 272 patients were assigned to receive SAPT
Myocardial infarction
It can be seen that DAPT using cilostazol is superior to SAPT using clopidogrel or aspirin in preventing stroke recurrence and vascular events, and does not increase the risk of bleeding in patients with intracranial artery stenosis after stroke
.
.
Original source:
Original source:Shinichiro Uchiyama.